These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27246630)

  • 1. Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma.
    Uslu U; Schuler G; Dörrie J; Schaft N
    Exp Dermatol; 2016 Nov; 25(11):872-879. PubMed ID: 27246630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of CD8(+) T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy.
    Höfflin S; Prommersberger S; Uslu U; Schuler G; Schmidt CW; Lennerz V; Dörrie J; Schaft N
    Cancer Biol Ther; 2015; 16(9):1323-31. PubMed ID: 26178065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer.
    Simon B; Harrer DC; Schuler-Thurner B; Schuler G; Uslu U
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31137488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell receptor gene therapy of established tumors in a murine melanoma model.
    Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
    J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy.
    Simon B; Harrer DC; Thirion C; Schuler-Thurner B; Schuler G; Uslu U
    J Immunol Methods; 2019 Sep; 472():55-64. PubMed ID: 31207210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
    Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
    Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
    Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
    Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas.
    Burns WR; Zhao Y; Frankel TL; Hinrichs CS; Zheng Z; Xu H; Feldman SA; Ferrone S; Rosenberg SA; Morgan RA
    Cancer Res; 2010 Apr; 70(8):3027-33. PubMed ID: 20395199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing.
    Ouchi Y; Patil A; Tamura Y; Nishimasu H; Negishi A; Paul SK; Takemura N; Satoh T; Kimura Y; Kurachi M; Nureki O; Nakai K; Kiyono H; Uematsu S
    Int Immunol; 2018 Apr; 30(4):141-154. PubMed ID: 29617862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.
    Hanada KI; Yu Z; Chappell GR; Park AS; Restifo NP
    JCI Insight; 2019 May; 4(10):. PubMed ID: 31092734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
    Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.
    Straetemans T; Berrevoets C; Coccoris M; Treffers-Westerlaken E; Wijers R; Cole DK; Dardalhon V; Sewell AK; Taylor N; Verweij J; Debets R
    Mol Ther; 2015 Feb; 23(2):396-406. PubMed ID: 25363716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel strategy in the elimination of disseminated melanoma cells: chimeric receptors endow T cells with tumor specificity.
    Abken H; Hombach A; Heuser C; Reinhold U
    Recent Results Cancer Res; 2001; 158():249-64. PubMed ID: 11092052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity.
    Kosaka A; Ohkuri T; Ikeura M; Kohanbash G; Okada H
    Biochem Biophys Res Commun; 2015 Mar; 458(3):549-554. PubMed ID: 25677619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
    Yee C; Thompson JA; Byrd D; Riddell SR; Roche P; Celis E; Greenberg PD
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16168-73. PubMed ID: 12427970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma.
    Clemons-Miller AR; Chatta GS; Hutchins L; Angtuaco EJ; Ravaggi A; Santin AD; Cannon MJ
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):917s-924s. PubMed ID: 11300492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
    Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
    Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.